Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions

摘要: Eosinophils are pro-inflammatory cells that make a major contribution to allergic diseases affecting the upper and lower airways, skin gastrointestinal tract. IL-5 is central eosinophil maturation release from bone marrow, subsequent accumulation, activation persistence of eosinophils in tissues. Reslizumab Ception Therapeutics Inc humanized mAb with potent IL-5-neutralizing effects. The agent inhibited eosinophilia several animal models; reductions airway hyperactivity bronchoconstriction were also observed. Clinical trials for reslizumab have been completed small number patients asthma, nasal polyposis, hypereosinophilic syndrome (HES) gastroenteritis (EG). Eosinophil depletion was observed all trials, but clinical responses often limited, particularly asthma; furthermore, some exhibited rebound disease levels greater than baseline. At time publication, phase II/III III ongoing eosinophilic esophagitis (EE), II trial asthma. potentially efficacious well-tolerated treatment EG, EE, HES although more required understand underlying mechanism rebound. However, rarity conditions such as HES, EE EG makes conduct difficult.